Innovent stock slips as Hong Kong trading shows 2.12 percent drop
Published on 09/02/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Innovent Biologics, Inc. (KYG5420K1094) stock traded at HKD 101.600 in Hong Kong on September 2, 2026, down 2.12 percent from the previous close of HKD 103.800. Yahoo Finance also showed a market capitalization of HKD 177.177 billion, a 52-week range of HKD 69.550 to HKD 112.700, and volume of 10,529,706 shares.
Stock stays above last quarter's scale
The latest Yahoo Finance snapshot puts Innovent's revenue at HKD 15.71 billion on a trailing 12-month basis, net income attributable to common shareholders at HKD 1.23 billion, and diluted EPS at HKD 0.550. That mix leaves the stock on a trailing P/E of 184.73 and a profit margin of 7.85 percent.
Three numbers matter now
The comparison is sharp: the share price is 9.86 percent below the 52-week high of HKD 112.700, while the YTD gain still stands at 33.25 percent and the 1-year return is minus 3.61 percent. In other words, the market still values growth, but the current quote sits closer to the upper half of the yearly range than to the low.
Innovent Biologics profile and filings
The company file and investor section are useful for checking the newest pipeline, business updates, and report history.
TYVYT remains central
Innovent's portfolio still centers on TYVYT, the company's commercial antibody franchise, alongside products such as BYVASDA, SULINNO, and HALPRYZA. Yahoo Finance describes the group as a biotechnology company with 8,754 full-time employees and a fiscal year end on December 31.
Hong Kong close matters
At 4:08:12 PM GMT+8 on September 2, 2026, the Hong Kong quote stood at HKD 101.600. That left the stock below the previous close, but still inside the 52-week band that stretches to HKD 112.700.
Innovent Biologics at a glance
- Company: Innovent Biologics, Inc.
- ISIN: KYG5420K1094
- Ticker: 1801.HK
- Trading venue: Hong Kong Stock Exchange
- Price (as of September 2, 2026, 4:08:12 PM GMT+8): HKD 101.600
- Market capitalization: HKD 177.177 billion (as of September 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Hang Seng Composite Index
